BioMerieux : Résultats semestriels au 30 juin 2023 - 1er septembre 2023
September 01, 2023 at 07:37 pm IST
Share
H1 2023 RESULTS & OUTLOOK
September 2023
Disclaimer
This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.
The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.
This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.
2023 H1 results presentation / B I O M É R I E U X
2
1. H1 2023 Business Highlights
Pierre BOULUD
2. H1 2023 Financial performance
Guillaume BOUHOURS
3. CSR & 2023 Outlook
Pierre BOULUD
Pierre BOULUD, CEO
H1 2023
Business highlights
KEY FINANCIAL HIGHLIGHTS
SALES
CONTRIBUTIVE
LEVERAGE
EBIT
+8.3%*
Net Debt / EBITDA
(+11%* excl. RP)
16,5% of sales
Remarkable performance of microbiology & industrial applications, both volumes and prices
Success of BIOFIRE non respiratory panels, strengthening long term leadership in syndromic
Resilience of BIOFIRE respiratory panels sales post COVID pandemic
Continuous investment to nurture future growth
*at constant exchange rates and scope of consolidation
5
2023 H1 results presentation / B I O M É R I E U X
BioMérieux SA published this content on 01 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 September 2023 14:06:03 UTC.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
BIOMÉRIEUX 
